Literature DB >> 9753046

Distribution of prostaglandin IP and EP receptor subtypes and isoforms in platelets and human umbilical artery smooth muscle cells.

B Z Paul1, B Ashby, S B Sheth.   

Abstract

Prostaglandins act through specific receptors to stimulate cyclic AMP formation which inhibits platelet activation and relaxes vascular smooth muscle. We have used RT-PCR combined with Southern blot analysis to determine the subtypes of prostaglandin receptor on platelets. Platelets expressed the EP4 rather than the EP2 prostaglandin EP receptor subtype, whereas vascular smooth muscle cells predominantly expressed the EP2 receptor. The IP receptor, which binds prostacyclin and couples to stimulation of adenylyl cyclase, and three isoforms of the inhibitory EP3 receptor were equally expressed in platelets, HEL cells and umbilical artery smooth muscle cells. The EP3-II isoform showed variation in level of expression among the three cell types. As a positive control for the presence of platelet RNA, PCR was performed using primers specific for the alpha chain of the platelet membrane glycoprotein Ib. As a negative control for the absence of T and B cell contamination in the platelet RNA, PCR was performed using primers specific for the cell specific cluster determinants CD2 (a T-cell marker) and CD20 (a B-cell marker). The finding that platelets express both stimulatory and inhibitory prostaglandin receptors provides confirmation of a homeostatic model of regulation of platelet adenylyl cyclase previously proposed.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9753046     DOI: 10.1046/j.1365-2141.1998.00910.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  10 in total

1.  PGE2 decreases reactivity of human platelets by activating EP2 and EP4.

Authors:  James P Smith; Elias V Haddad; Jason D Downey; Richard M Breyer; Olivier Boutaud
Journal:  Thromb Res       Date:  2010-05-08       Impact factor: 3.944

2.  Activation of the murine EP3 receptor for PGE2 inhibits cAMP production and promotes platelet aggregation.

Authors:  J E Fabre; M Nguyen; K Athirakul; K Coggins; J D McNeish; S Austin; L K Parise; G A FitzGerald; T M Coffman; B H Koller
Journal:  J Clin Invest       Date:  2001-03       Impact factor: 14.808

Review 3.  Understanding the role of prostaglandin E2 in regulating human platelet activity in health and disease.

Authors:  Eitan A Friedman; Martin L Ogletree; Elias V Haddad; Olivier Boutaud
Journal:  Thromb Res       Date:  2015-05-28       Impact factor: 3.944

4.  The role of PGE(2) in human atherosclerotic plaque on platelet EP(3) and EP(4) receptor activation and platelet function in whole blood.

Authors:  Lisa J Schober; Anna L Khandoga; Suman Dwivedi; Sandra M Penz; Takayuki Maruyama; Richard Brandl; Wolfgang Siess
Journal:  J Thromb Thrombolysis       Date:  2011-08       Impact factor: 2.300

Review 5.  Anti-platelet therapy: cyclo-oxygenase inhibition and the use of aspirin with particular regard to dual anti-platelet therapy.

Authors:  Timothy D Warner; Sven Nylander; Carl Whatling
Journal:  Br J Clin Pharmacol       Date:  2011-10       Impact factor: 4.335

6.  Inhibition of Rac activation as a mechanism for negative regulation of actin cytoskeletal reorganization and cell motility by cAMP.

Authors:  Shin-ya Nagasawa; Noriko Takuwa; Naotoshi Sugimoto; Hiroshi Mabuchi; Yoh Takuwa
Journal:  Biochem J       Date:  2005-02-01       Impact factor: 3.857

7.  International Union of Basic and Clinical Pharmacology. CIX. Differences and Similarities between Human and Rodent Prostaglandin E2 Receptors (EP1-4) and Prostacyclin Receptor (IP): Specific Roles in Pathophysiologic Conditions.

Authors:  Xavier Norel; Yukihiko Sugimoto; Gulsev Ozen; Heba Abdelazeem; Yasmine Amgoud; Amel Bouhadoun; Wesam Bassiouni; Marie Goepp; Salma Mani; Hasanga D Manikpurage; Amira Senbel; Dan Longrois; Akos Heinemann; Chengcan Yao; Lucie H Clapp
Journal:  Pharmacol Rev       Date:  2020-10       Impact factor: 25.468

8.  Vascular wall-produced prostaglandin E2 exacerbates arterial thrombosis and atherothrombosis through platelet EP3 receptors.

Authors:  Sabrina Gross; Peggy Tilly; Didier Hentsch; Jean-Luc Vonesch; Jean-Etienne Fabre
Journal:  J Exp Med       Date:  2007-01-22       Impact factor: 14.307

Review 9.  Effect of Prostanoids on Human Platelet Function: An Overview.

Authors:  Steffen Braune; Jan-Heiner Küpper; Friedrich Jung
Journal:  Int J Mol Sci       Date:  2020-11-27       Impact factor: 5.923

Review 10.  Pyrrolotriazinone as an Underexplored Scaffold in Drug Discovery.

Authors:  Tony Ge; Jean-Christophe Cintrat
Journal:  Pharmaceuticals (Basel)       Date:  2021-12-06
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.